

Chapter 155

Lupus Erythematosus

Melissa I. Costner & Richard D. Sontheimer

REFERENCES

1. Tan EM et al: The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 25(11):1271-1277, 1982
2. Watanabe T, Tsuchida T: Classification of lupus erythematosus based upon cutaneous manifestations. Dermatological, systemic and laboratory findings in 191 patients. *Dermatology* 190(4):277-283, 1995
3. Tebbe B, Orfanos CE: Epidemiology and socio-economic impact of skin disease in lupus erythematosus. *Lupus* 6(2):96-104, 1997
4. Robinson D et al: Impact of systemic lupus erythematosus on health, family, and work: the patient perspective. *Arthritis Care Res (Hoboken)* 62(2):266-273, 2010
5. Ferraz LB et al: The impact of lupus erythematosus cutaneous on the quality of life: The Brazilian-Portuguese version of DLQI. *Qual Life Res* 15(3):565-570, 2006
6. Durosaro O et al: Incidence of cutaneous lupus erythematosus, 1965-2005: A population-based study. *Arch Dermatol* 145(3):249-253, 2009
PubMed PMID: 19289752
7. Lin JH et al: Pathophysiology of cutaneous lupus erythematosus. *Clin Rev Allergy Immunol* 33(1-2):85-106, 2007
8. Werth VP, Bashir M, Zhang W: Photosensitivity in rheumatic diseases. *J Investig Dermatol Symp Proc* 9(1):57-63, 2004
9. Millard TP et al: A candidate gene analysis of three related photosensitivity disorders: Cutaneous lupus erythematosus, polymorphic light eruption and actinic prurigo. *Br J Dermatol* 145(2):229-236, 2001
10. Karp DR: Complement and systemic lupus erythematosus. *Curr Opin Rheumatol* 17(5):538-542, 2005
11. Racila DM, Sontheimer RD: C1q inhibits autoantibody binding to calreticulin. *Lupus* 8(4):300-304, 1999
12. Ackerman LS: Sex hormones and the genesis of autoimmunity. *Arch Dermatol* 142(3):371-376, 2006
13. Casciola-Rosen L, Rosen A: Ultraviolet light-induced keratinocyte apoptosis: A potential mechanism for the induction of skin lesions and autoantibody production in LE. *Lupus* 6(2):175-180, 1997
14. Meller S et al: Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: An amplification cycle triggering cutaneous lupus erythematosus. *Arthritis Rheum* 52(5):1504-1516, 2005
15. Lehmann P, Homey B: Clinic and pathophysiology of photosensitivity in lupus erythematosus. *Autoimmun Rev* 8(6):456-461, 2009
16. Moghadam-Kia S et al: Cross-sectional analysis of a collaborative web-based database for lupus erythematosus-associated skin lesions: Prospective enrollment of 114 patients. *Arch Dermatol* 145(3):255-260, 2009
17. Rahman P, Gladman DD, Urowitz MB: Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. *J Rheumatol* 25(9):1716-1719, 1998
18. Hardy CJ et al: Smoking history, alcohol consumption, and systemic lupus erythematosus: A case-control study. *Ann Rheum Dis* 57(8):451-455, 1998
19. Jewell ML, McCauliffe DP: Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. *J Am Acad Dermatol* 42(6):983-987, 2000
20. Kang I, Park SH: Infectious complications in SLE after immunosuppressive therapies. *Curr Opin Rheumatol* 15(5):528-534, 2003
21. Yung RL et al: Mechanism of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. *J Immunol* 154(6):3025-3035, 1995
22. Charles J et al: Plasmacytoid dendritic cells and dermatological disorders: Focus on their role in autoimmunity and cancer. *Eur J Dermatol* 20(1):16-23, 2010
23. Pascual V, Banchereau J, Palucka AK: The central role of dendritic cells and interferon-alpha in SLE. *Curr Opin Rheumatol* 15(5):548-556, 2003
24. Wenzel J et al: Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus. *Arch Dermatol Res* 301(1):83-86, 2009

- 24a. Bosch X: Systemic Lupus Erythematosus and the Neutrophil. *N Engl J Med* **365**(8):758-760, Aug 25; 2011
25. Kalia S, Dutz JP: New concepts in antimalarial use and mode of action in dermatology. *Dermatol Ther* **20**(4):160-174, 2007
26. Malcangi G et al: Bullous SLE: Response to methotrexate and relationship with disease activity. *Lupus* **12**(1):63-66, 2003
27. Palucka AK et al: Cross-regulation of TNF and IFN-alpha in autoimmune diseases. *Proc Natl Acad Sci U S A* **102**(9):3372-3377, 2005
28. Wenzel J et al: The expression of human leukocyte antigen-DR and CD25 on circulating T cells in cutaneous lupus erythematosus and correlation with disease activity. *Exp Dermatol* **14**(6):454-459, 2005
29. Sawalha AH, Harley JB: Antinuclear autoantibodies in systemic lupus erythematosus. *Curr Opin Rheumatol* **16**(5):534-540, 2004
30. Ting W et al: Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): A case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. *Lupus* **13**(12):941-950, 2004
31. Chaudhry SI, Murphy LA, White IR: Subacute cutaneous lupus erythematosus: A paraneoplastic dermatosis? *Clin Exp Dermatol* **30**(6):655-658, 2005
32. Jou IM, Liu MF, Chao SC: Widespread cutaneous necrosis associated with antiphospholipid syndrome. *Clin Rheumatol* **15**(4):394-398, 1996
33. Franceschini F et al: Chilblain lupus erythematosus is associated with antibodies to SSA/Ro. *Lupus* **8**(3):215-219, 1999
34. Hedrich CM et al: Chilblain lupus erythematosus—a review of literature. *Clin Rheumatol* **27**(8):949-954, 2008
35. Viguier M et al: Clinical and histopathologic features and immunologic variables in patients with severe chilblains. A study of the relationship to lupus erythematosus. *Medicine (Baltimore)* **80**(3):180-188, 2001
36. Lee-Kirsch MA et al: A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. *J Mol Med* **85**(5):531-537, 2007
37. Callen JP: Clinically relevant information about cutaneous lupus erythematosus. *Arch Dermatol* **145**(3):316-319, 2009
38. Maize JC Jr, Costner M: Tumid lupus erythematosus: A form of lupus erythematosus. *Arch Dermatol* **146**(4):451; author reply 450-451
39. Ruiz H, Sanchez JL: Tumid lupus erythematosus. *Am J Dermatopathol* **21**(4):356-360, 1999
40. Kuhn A et al: Phototesting in lupus erythematosus: A 15-year experience. *J Am Acad Dermatol* **45**(1):86-95, 2001
41. Dekle CL et al: Lupus tumidus. *J Am Acad Dermatol* **41**(2 Pt 1):250-253, 1999
42. Vieira V et al: Lupus erythematosus tumidus: A series of 26 cases. *Int J Dermatol* **45**(5):512-517, 2006
43. Stead J et al: Coexistence of tumid lupus erythematosus with systemic lupus erythematosus and discoid lupus erythematosus: A report of two cases of tumid lupus. *J Clin Rheumatol* **14**(6):338-341, 2008
44. Tomasini D et al: Plasmacytoid dendritic cells: An overview of their presence and distribution in different inflammatory skin diseases, with special emphasis on Jessner's lymphocytic infiltrate of the skin and cutaneous lupus erythematosus. *J Cutan Pathol* **37**:1132-1139, 2010
45. Callen JP: Clinically relevant information about cutaneous lupus erythematosus. *Arch Dermatol* **145**(3):316-319, 2009 PubMed PMID: 19289766
46. Kuhn A et al: Clinical manifestations of cutaneous lupus erythematosus. *J Dtsch Dermatol Ges* **5**(12):1124-1137, 2007 English, German. PubMed PMID: 18042093
47. Obermoser G et al: Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates. *Lupus* **19**(9):1050-1070, 2010 PubMed PMID: 20693199
48. Sontheimer RD, Henderson CL, Grau RH: Drug-induced subacute cutaneous lupus erythematosus: A paradigm for bedside-to-bench patient-oriented translational clinical investigation. *Arch Dermatol Res* **301**(1):65-70, 2009
49. Suess A, Sticherling M: Leflunomide in subacute cutaneous lupus erythematosus – two sides of a coin. *Int J Dermatol* **47**(1):83-86, 2008
50. Parodi A et al: Measuring the activity of the disease in patients with cutaneous lupus erythematosus. *Br J Dermatol* **142**(3):457-460, 2000
51. Zecevic RD et al: Skin lesions—an indicator of disease activity in systemic lupus erythematosus? *Lupus* **10**(5):364-367, 2001

52. Vila LM et al: Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus. *Lupus* 9(2):110-115, 2000
53. Satirapoj B et al: Predictors of renal involvement in patients with systemic lupus erythematosus. *Asian Pac J Allergy Immunol* 25(1):17-25, 2007
54. Yell JA, Mbuagbaw J, Burge SM: Cutaneous manifestations of systemic lupus erythematosus. *Br J Dermatol* 135(3):355-362, 1996
55. Jonsson R et al: Oral mucosal lesions in systemic lupus erythematosus—a clinical, histopathological and immunopathological study. *J Rheumatol* 11(1):38-42, 1984
56. Burge SM et al: Mucosal involvement in systemic and chronic cutaneous lupus erythematosus. *Br J Dermatol* 121(6):727-741, 1989
57. Cardinali C et al: The spectrum of cutaneous manifestations in lupus erythematosus—the Italian experience. *Lupus* 9(6):417-423, 2000
58. Calamia KT, Balabanova M: Vasculitis in systemic lupus erythematosus. *Clin Dermatol* 22(2):148-156, 2004
59. Walling HW, Sontheimer RD: Cutaneous lupus erythematosus: Issues in diagnosis and treatment. *Am J Clin Dermatol* 10(6):365-381, 2009
60. Ramos-Casals M et al: Vasculitis in systemic lupus erythematosus: Prevalence and clinical characteristics in 670 patients. *Medicine (Baltimore)* 85(2):95-104, 2006
61. Bouaziz JD et al: Cutaneous lesions of the digits in systemic lupus erythematosus: 50 cases. *Lupus* 16(3):163-167, 2007 PubMed PMID: 17432100
62. Urowitz MB et al: Nail lesions in systemic lupus erythematosus. *J Rheumatol* 5(4):441-447, 1978
63. Tosti A: The nail apparatus in collagen disorders. *Semin Dermatol* 10(1):71-76, 1991
64. Wollina U et al: Lupus erythematosus-associated red lunula. *J Am Acad Dermatol* 41(3 Pt 1):419-421, 1999
65. Van der Horst JC, Cirkel PK, Nieboer C: Mixed lichen planus-lupus erythematosus disease: a distinct entity? Clinical, histopathological and immunopathological studies in six patients. *Clin Exp Dermatol* 8(6):631-640, 1983
66. Baird JS et al: Systemic lupus erythematosus with acanthosis nigricans, hyperpigmentation, and insulin receptor antibody. *Lupus* 6(3):275-278, 1997
67. Boyd AS, King LE Jr: Middermal elastolysis in two patients with lupus erythematosus. *Am J Dermatopathol* 23(2):136-138, 2001
68. Massone C et al: Multiple eruptive dermatofibromas in patients with systemic lupus erythematosus treated with prednisone. *Int J Dermatol* 41(5):279-281, 2002
69. Tlacuilo-Parra JA, Guevara-Gutierrez E, Salazar-Paramo M: Acquired ichthyosis associated with systemic lupus erythematosus. *Lupus* 13(4):270-273, 2004
70. Verneuil L et al: Interstitial granulomatous dermatitis with cutaneous cords and arthritis: A disorder associated with autoantibodies. *J Am Acad Dermatol* 45(2):286-291, 2001
71. Lee LA, Weston WL: Cutaneous lupus erythematosus during the neonatal and childhood periods. *Lupus* 6(2):132-138, 1997
72. David-Bajar KM, Davis BM: Pathology, immunopathology, and immunohistochemistry in cutaneous lupus erythematosus. *Lupus* 6(2):145-157, 1997
73. Crowson AN, Magro C: The cutaneous pathology of lupus erythematosus: A review. *J Cutan Pathol* 28(1):1-23, 2001
74. Baltaci M, Fritsch P: Histologic features of cutaneous lupus erythematosus. *Autoimmun Rev* 8(6):467-473, 2009
75. Park HS et al: Lupus erythematosus panniculitis: Clinicopathological, immunophenotypic, and molecular studies. *Am J Dermatopathol* 32(1):24-30, 2010
76. Albrecht J et al: The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An outcome instrument for cutaneous lupus erythematosus. *J Invest Dermatol* 125(5):889-894, 2005
77. Bonilla-Martinez ZL et al: The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. *Arch Dermatol* 144(2):173-180, 2008
78. Ting WW, Sontheimer RD: Local therapy for cutaneous and systemic lupus erythematosus: Practical and theoretical considerations. *Lupus* 10(3):171-184, 2001
79. Kreuter A et al: Pimecrolimus 1% cream for cutaneous lupus erythematosus. *J Am Acad Dermatol* 51(3):407-410, 2004
80. Lampropoulos CE et al: Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: A possible alternative. *Rheumatology (Oxford)* 43(11):1383-1385, 2004

81. von Pelchrzim R et al: Efficacy of topical tacrolimus in the treatment of various cutaneous manifestations of lupus erythematosus. *Int J Dermatol* **45**(1):84-85, 2006
82. Barikbin B et al: Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: A double-blind, randomized pilot study. *Clin Exp Dermatol* **34**(7):776-780, 2009
83. Madan V, August PJ, Chalmers RJ: Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: A cohort study. *Clin Exp Dermatol* **35**(1):27-30
84. Costner MI, Sontheimer RD, Provost TT: Lupus Erythematosus. In: *Cutaneous Manifestations of Rheumatic Diseases*, 2nd edition, edited by RD Sontheimer, TT Provost. Philadelphia: Lippincott Williams & Wilkins, 2004, pp. 15-64
85. Neri R et al: A case of SLE with acute, subacute and chronic cutaneous lesions successfully treated with Dapsone. *Lupus* **8**(3):240-243, 1999
86. Briani C et al: Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus. *Autoimmunity* **38**(7):549-555, 2005
87. Wu JJ et al: Thalidomide: Dermatological indications, mechanisms of action and side-effects. *Br J Dermatol* **153**(2):254-273, 2005
88. Shah A et al: Lenalidomide for the treatment of resistant discoid lupus erythematosus. *Arch Dermatol* **145**(3):303-306, 2009
89. Dooley MA, Ginzler EM: Newer therapeutic approaches for systemic lupus erythematosus: Immunosuppressive agents. *Rheum Dis Clin North Am* **32**(1):91-102, ix, 2006
90. Goyal S, Nousari HC: Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. *J Am Acad Dermatol* **45**(1):142-144, 2001
91. Schanz S et al: Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. *Br J Dermatol* **147**(1):174-178, 2002
92. Cetkovska P, Pizinger K: Coexisting subacute and systemic lupus erythematosus after terbinafine administration: Successful treatment with mycophenolate mofetil. *Int J Dermatol* **45**(3):320-322, 2006
93. Hanjani NM, Nousari CH: Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement. *Arch Dermatol* **138**(12):1616-1618, 2002
94. Pisoni CN et al: Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: Poor results with mycophenolate mofetil. *Clin Exp Rheumatol* **23**(3):393-396, 2005
95. Carneiro JR, Sato EI: Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. *J Rheumatol* **26**(6):1275-1279, 1999
96. Fabbri P et al: Cutaneous lupus erythematosus: Diagnosis and management. *Am J Clin Dermatol* **4**(7):449-465, 2003
97. Norman R, Greenberg RG, Jackson JM: Case reports of etanercept in inflammatory dermatoses. *J Am Acad Dermatol* **54**(3 Suppl 2):S139-S142, 2006
98. Fautrel B et al: Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: Comment on the article by Pisetsky and the letter from Aringer et al. *Arthritis Rheum* **46**(5):1408-1409; author reply 1409, 2002
99. Aringer M et al: Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: An open-label study. *Arthritis Rheum* **50**(10):3161-3169, 2004
100. Ramos-Casals M et al: Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases. *Medicine (Baltimore)* **86**(4):242-251, 2007
101. Wetter DA, Davis MD: Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. *Mayo Clin Proc* **84**(11):979-984, 2009
102. Bleumink GS et al: Etanercept-induced subacute cutaneous lupus erythematosus. *Rheumatology (Oxford)* **40**(11):1317-1319, 2001
103. Scheinfeld N: A review of rituximab in cutaneous medicine. *Dermatol Online J* **12**(1):3, 2006
104. Uthman I et al: Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: Report of a case. *Dermatology* **216**(3):257-259, 2008
105. Kieu V et al: Refractory subacute cutaneous lupus erythematosus successfully treated with rituximab. *Australas J Dermatol* **50**(3):202-206, 2009
106. Lateef A, Petri M: Biologics in the treatment of systemic lupus erythematosus. *Curr Opin Rheumatol* **22**(5):504-509, 2010
107. Clayton TH, Ogden S, Goodfield MD: Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab. *J Am Acad Dermatol* **54**(5):892-895, 2006

108. Usmani N, Goodfield M: Efalizumab in the treatment of discoid lupus erythematosus. *Arch Dermatol* **143**(7):873-877, 2007
109. Yao Y et al: Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. *Arthritis Rheum* **60**(6):1785-1796, 2009 (PubMed PMID: 19479852)
110. Tremblay JF, Carey W: Atrophic facial scars secondary to discoid lupus erythematosus: treatment using the Erbium:YAG laser. *Dermatol Surg* **27**(7):675-677, 2001
111. Walker SL, Harland CC: Carbon dioxide laser resurfacing of facial scarring secondary to chronic discoid lupus erythematosus. *Br J Dermatol* **143**(5):1101-1102, 2000
112. Erceg A et al: Efficacy and safety of pulsed dye laser treatment for cutaneous discoid lupus erythematosus. *J Am Acad Dermatol* **60**(4):626-632, 2009

